Artificial Intelligence View All AI, ML and Deep Learning Auto ML Data Labelling Synthetic Data Conversational AI NLP Text-to-Speech Security View All Data Security and Privacy Network Security and Privacy Software Security Computer Hardware Security Cloud and Data Storage Security Data Infrastructure View All Data Science Data Management Data Storage and Cloud Big Data and Analytics Data Networks Automation View All Industrial Automation Business Process Automation Development Automation Robotic Process Automation Test Automation Enterprise Analytics View All Business Intelligence Disaster Recovery Business Continuity Statistical Analysis Predictive Analysis More Data Decision Makers Virtual Communication Team Collaboration UCaaS Virtual Reality Collaboration Virtual Employee Experience Programming & Development Product Development Application Development Test Management Development Languages Press Release SFA Therapeutics to Present Human Psoriasis Data for Microbiome-based Drug (SFA002) at the Global Biotech Entrepreneur Forum and the BIO International Convention Share on Facebook Share on X Share on LinkedIn Also Presenting Preclinical Data on Two Additional Pipeline Products PHILADELPHIA–(BUSINESS WIRE)–May 31, 2019– SFA Therapeutics, Inc. will be presenting human Psoriasis data on its human-microbiome-based drug (SFA002) as well as pre-clinical data for two additional pipeline products at the Global Biotech Entrepreneur Forum on June 2 nd at the Science Education and Research Center at Temple University, and during the BIO International Convention in Philadelphia on June 4, 2019 at the Philadelphia Convention Center.
The first presentation takes place at the Temple University Science and Education Research Center, at 9 AM on June 2 nd at the Global Biotech Entrepreneur Forum in Philadelphia. The second presentation takes place June 4th in Theater 4, Level 200, From 11:15 AM To 11:30 AM the BIO International Convention at the Philadelphia Convention Center.
 In each talk, Dr. Ira C. Spector, CEO, will provide an overview of the company, and human data for its microbiome-based drug SFA002 in the treatment of Psoriasis, as well as transgenic animal data on SFA001 in prevention of the progression of Hepatitis B-mediated Chronic Liver Disease (CLD) to Hepatocellular Carcinoma (HCC Liver Cancer), and in the direct treatment of HCC Liver Cancer.
The company will also discuss early phase research into preventing relapse/recurrence in Chronic Lymphocytic Leukemia (CLL) and Acute Myelogenous Leukemia (AML).
About SFA Therapeutics SFA Therapeutics, Inc. is a bio-pharmaceutical company focused on new human microbiome-based advancements in the treatment of inflammatory diseases, targeting NF-KB mediated pathways. Chronic inflammation has been implicated in a wide range of diseases, including Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Lupus (SLE), Inflammatory Bowel Disease (IBD), Crohn’s disease, Liver Disease, and relapse/recurrence in AML and CML.
SFA’s small-molecule drugs are derived from natural substances produced in the human microbiome and enable a new platform for developing safer treatments for inflammatory diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190531005081/en/ Josh Weinstein jwEinstein Strategic Messaging, Inc.
610-438-8853 jw@jweinstein.guru Dr. Ira C. Spector, CEO, SFA Therapeutics, Inc.
267-584-1080 iraspector@sfatherapeutics.com VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative enterprise technology and transact.
Discover our Briefings.
VentureBeat Homepage Follow us on Facebook Follow us on X Follow us on LinkedIn Follow us on RSS Press Releases Contact Us Advertise Share a News Tip Contribute to DataDecisionMakers Careers Privacy Policy Terms of Service Do Not Sell My Personal Information © 2023 VentureBeat.
 All rights reserved.
